Business
CytoSorbents Partners with InvoSurg and Surgical Partners to Commercialize CytoSorb® in the U.S. Northeast, Mid-Atlantic, and Florida under FDA Emergency Use Authorization for COVID-19
MONMOUTH JUNCTION, N.J., Aug. 17, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) has entered into separate agreements with InvoSurg Inc. and
About this update from Cytosorbents Corporation
[{"type":"text","content":"MONMOUTH JUNCTION, N.J., Aug. 17, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) has entered into separate agreements with InvoSurg Inc. and Surgical Partners to commercialize CytoSorb® under its FDA Emergency Use Authorization (EUA) in adult, critically-ill, COVID-19 patients with imminent or confirmed respiratory failure. Covering 15 states, Surgical Partners and InvoSurg will work with CytoSorbents to sell and distribute CytoSorb in Florida, and the Northeast and Mid-Atlantic United States, from Maine to Virginia, respectively.\n\n \n \n \n \n \n \n\n \nThese agreements follow a very positive initial reception and usage of CytoSorb in the U.S. after FDA Emergency Use Authorization of CytoSorb was granted in April 2020. CytoSorbents is now aggressively expanding CytoSorb availability, marketing, and sales opportunities across the U.S. to help address the current and expected future waves of COVID-19 infection in the country.\nMr. Kenneth Shann, CCP, Director of Business Development and Training at InvoSurg stated, \"We are thrilled to add the CytoSorb cytokine adsorber to our extensive portfolio in order to provide solutions to our customers and their sickest patients battling COVID-19.\"\nMr. Bo Arble, Vice President of Surgical Partners stated, \"COVID-19 continues to be a major challenge here in Florida. COVID-19 patients that are admitted to the ICU with imminent or confirmed respiratory failure generally have poor outcomes and can be difficult to treat. With the availability of CytoSorb under FDA EUA, we now have an exciting treatment option to potentially help these patients by removing excessive cytokines, or cytokine storm, from the bloodstream.\"\nMr. Chris Cramer, Vice President of Business Development of CytoSorbents stated, \"CytoSorb is the only FDA EUA blood purification technology to target cytokine storm reduction using CytoSorbents' proprietary, highly biocompatible polymer beads. These beads combine more than 7 football fields of surface area in a single, easy-to-use, whole blood cytokine adsorber. We believe CytoSorb can play an important role in helping front-line physicians and healthcare workers better manage their COVID-19 patients. We are excited to work with Surgical Partners and InvoSurg to bring our therapy to more hospitals here in the United States.\"\nMr. Vincent Capponi, President a...